Ikris Pharma Network is a global pharmaceutical company dedicated to improving access to essential medicines. We offer three key services: Named Patient Management, Indian Generic Medicines, and Clinical Trial Sourcing to meet the needs of patients and healthcare providers worldwide. With a strong presence in key regions like Europe, Asia, Japan, Australia, and Latin America, IPN is dedicated to making life-saving medicines accessible and affordable.

In today’s healthcare landscape, accessing critical medicines and managing clinical trials can be complex. IPN simplifies this process with its three key services. These services are designed to meet the needs of healthcare professionals and patients worldwide.

Our Named Patient Management or Named Patient Program service helps patients obtain medicines not yet approved in their home countries. Through Indian Generic Medicines, we provide affordable, high-quality alternatives to branded drugs. Lastly, our Clinical Trial Sourcing service (RLD Supply / Comparator Sourcing from India, Europe, USA, Japan, Australia, etc) ensures that clinical trials have the necessary medications to advance research. At Ikris, we strive to make vital treatments accessible to everyone, no matter where they are.

Named Patient Management:

Named Patient Management is a critical service provided by IPN to help patients access medicines that are not yet approved in their home countries. When a specific drug is needed for a serious medical condition but is unavailable locally, IPN steps in to facilitate the import of unlicensed medicines. This service ensures that patients receive the required treatment while adhering to all necessary regulations and approvals from relevant authorities.

Key features of IPN’s Named Patient Management include:

• Global access to unapproved or unregistered drugs.
• Compliance with local and international regulations.
• Coordination with healthcare providers to ensure timely delivery.

Through this service, IPN has helped numerous patients gain access to essential treatments that would otherwise be out of reach.

Indian Generic Medicines:

IPN is a trusted supplier of Indian Generic Medicines, offering an extensive range of high-quality drugs at competitive prices. These medicines are crucial for patients who require affordable treatment options, especially in countries where the cost of branded medicines is prohibitively high. IPN works directly with certified manufacturers in India to ensure that all medicines meet the highest standards of quality and efficacy.

Why choose Indian Generic Medicines through IPN?

• Cost-effective alternatives to expensive branded drugs.

• The wide availability of essential medicines for various medical conditions.
• Strict quality control and adherence to international standards.

By supplying Indian Generic Medicines, IPN plays a vital role in reducing healthcare costs and expanding access to life-saving treatments across the globe.

Clinical Trial Sourcing:

Clinical Trial Sourcing is another core service offered by IPN, specifically designed to support the needs of clinical researchers and pharmaceutical companies. IPN specializes in sourcing comparator drugs and other essential supplies for clinical trials, ensuring that research teams have everything they need to conduct their studies effectively.

• Advantages of IPN’s Clinical Trial Sourcing:
• Reliable supply chain management to ensure timely delivery.
• Access to a diverse range of comparator drugs.

Global reach, making it possible to source drugs from various regions.
With this service, IPN contributes to the advancement of medical research by providing the necessary resources to test new therapies and treatments.

Why Choose Ikris Pharma Network?

At IPN, our mission is to simplify the process of accessing critical medicines and clinical trial supplies. We understand the challenges faced by patients, doctors, and researchers in getting the right medications at the right time. That's why we've built a service that is not only reliable but also easy to use. Our team is committed to providing personalized support to ensure your needs are met promptly and efficiently.

Conclusion:
Ikris Pharma Network is committed to improving global healthcare by offering essential services that make a difference. Whether it’s providing access to unlicensed medicines, offering affordable Indian Generic Medicines, or supporting clinical research through Clinical Trial Sourcing, IPN is a trusted partner in the healthcare industry. Our dedication to quality, compliance, and affordability makes us a leader in the pharmaceutical sector.

By choosing IPN, healthcare providers and patients alike can benefit from a reliable source of essential medicines and services that meet the highest standards of quality and safety. For more information on how IPN can assist with your pharmaceutical needs, feel free to explore our services and get in touch.

FAQs: Global Reach of Ikris Pharma

How does Ikris Pharma Network (IPN) assist with the Named Patient Program in Europe?

IPN ensures compliance with European regulations while sourcing and supplying unapproved medicines on a named-patient basis, helping patients access critical treatments not yet available in their home country.

Can Ikris supply Indian Generic Medicines to Latin American Countries?

Yes, IPN specializes in sourcing and supplying high-quality Indian Generic Medicines to Latin American countries (Mexico, Guatemala, Honduras, Nicaragua, El Salvador, Costa Rica, Panama, Belize, Haiti, Cuba, Dominican Republic, Jamaica, Trinidad & Tobago, Barbados, St. Lucia, Grenada, St. Vincent & Grenadines, Antigua & Barbuda, Dominica, St. Kitts & Nevis, Brazil, Colombia, Argentina, Peru, Venezuela, Puerto Rico, Ecuador, Bolivia, Paraguay, Uruguay, Suriname, and Guyana), ensuring patients receive affordable and effective treatments.

Does Ikris Pharma Network offer services in Southeast Asia?

Yes, IPN provides Named Patient Management, Indian Generic Medicines, and Clinical Trial Sourcing services across Southeast Asia, ensuring access to essential treatments in this region.

How does Ikris Pharma Network handle unregistered medicines in the Middle East?

IPN works closely with regulatory authorities in the Middle East to import and supply unregistered medicines under the Named Patient Management program, ensuring patients receive necessary treatments.

Can IPN help with Clinical Trial Sourcing in Australia? 

Absolutely, IPN offers end-to-end Clinical Trial Sourcing services in Australia, ensuring that research institutions have timely access to the necessary drugs and comparators.

Is IPN’s service available in Africa?

Yes, IPN’s services, including Named Patient Management and the supply of Indian Generic Medicines, are available across various African countries (Nigeria, Ethiopia, Egypt, DR Congo, Tanzania, South Africa, Kenya, Sudan, Uganda, Algeria, Morocco, Ghana, Madagascar, Zimbabwe, Namibia, Botswana, etc, supporting healthcare access in the region.

What regions does IPN cover for Named Patient Programs? 

IPN’s Named Patient Programs cover multiple regions including Europe, Latin America, the Middle East, Southeast Asia, and Africa, ensuring global access to critical treatments.

How does Ikris ensure the quality of Indian Generic Medicines supplied to Gulf countries?

IPN sources Indian Generic Medicines from trusted manufacturers that comply with international quality standards, ensuring that patients in Gulf countries (Saudi Arabia, Bahrain, Kuwait, Iraq, Oman, Qatar, and the UAE) receive safe and effective treatments.

What are the benefits of using Ikris’s Clinical Trial Sourcing service in India? 

IPN’s Clinical Trial Sourcing service in India offers research institutions reliable access to essential drugs, timely procurement, and compliance with local regulations, thus supporting efficient and successful clinical trials.

What are the main export markets of Ikris Pharma for Indian Generic Medicines, including specific countries within each region?

The main export markets of Ikris are Western Europe (France, Germany, Ireland, Austria, Belgium, UK, Liechtenstein, Luxembourg, Monaco, Netherlands, Switzerland, Andorra), Australia, the Middle East (Bahrain, Cyprus, Egypt, UAE, Iran, Iraq, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Syria, Turkey, Yemen), Central America (Belize, Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua, Panama), Eastern Europe (Serbia, Slovakia, Russia, Bulgaria, Slovenia, Ukraine, Croatia, Czech Republic, Estonia, Lithuania, Moldova, Hungary, Kosovo, Latvia, Poland, Romania, Montenegro, North Macedonia, Albania, Belarus, Bosnia, Herzegovina), South America (Argentina, Bolivia, Brazil, Chile, Colombia, Guyana, Paraguay, Ecuador, Peru, Suriname, Uruguay, Venezuela), Asia (Maldives, Malaysia, Vietnam, Thailand, Singapore, Sri Lanka, Philippines, Japan, China, Indonesia, Bangladesh, Bhutan, Afghanistan), North America (Mexico,, Canada, US, Cuba, Jamaica, Haiti, and Africa.